Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy in Metastatic Melanoma
NCT02375984Phase 2Terminated
- Sponsor
- Providence Saint John's Cancer Institute
- Start
- Mar 2016
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in melanoma, sponsored by Providence Saint John's Cancer Institute. Started Mar 2016; status: terminated.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02375984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375984.